- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01599949
A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy
May 27, 2016 updated by: Janssen Research & Development, LLC
A Phase 2, Multicenter, Single-Arm, Study to Evaluate the Efficacy and Safety of Single-Agent Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy
The purpose of this study is to evaluate the efficacy and safety of ibrutinib in patients with mantle cell lymphoma who received at least 1 prior rituximab-containing chemotherapy regimen and who progressed after bortezomib therapy.
Study Overview
Detailed Description
This is a single-arm (all patients will receive the study drug) study to evaluate the efficacy and safety of ibrutinib in patients with mantle cell lymphoma (MCL) who have received at least 1 rituximab-containing chemotherapy regimen and who progressed after bortezomib therapy.
Approximately 110 eligible patients will be enrolled.
During the treatment phase, patients will receive 560 mg of ibrutinib by mouth once daily continuously until disease progression, unacceptable toxicity, or study end, whichever occurs first.
Treatment will be continuous (without interruption) and self-administered at home.
Doses can be held or reduced based on the severity of and the recovery from side effects of the study drug.
The sponsor will ensure that patients benefiting from treatment with ibrutinib will be able to continue treatment after the end of the study.
Data will be collected on disease response to the treatment, on progression-free survival, overall survival, and subsequent anti-MCL therapies.
Serial pharmacokinetic (study of what the body does to a drug) samples will be collected as detailed in the protocol.
Safety will be monitored throughout the study.
An interim analysis of the pharmacokinetic data will occur approximately 3 months after the scheduled pharmacokinetic sampling in Cycles 1 and 2 has been completed.
Data will be analyzed 1 year after the last patient is enrolled for the primary analysis and 2 years after last patient is enrolled for the final follow-up.
Study Type
Interventional
Enrollment (Actual)
120
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Brugge, Belgium
-
Gent, Belgium
-
-
-
-
-
Grenoble, France
-
Mulhouse N/A, France
-
Nantes, France
-
Pessac, France
-
Vandoeuvre Les Nancy, France
-
-
-
-
-
Afula, Israel
-
Beer Yaakov, Israel
-
Hadera, Israel
-
Haifa, Israel
-
Nahariya, Israel
-
Petah Tikva, Israel
-
Ramat Gan, Israel
-
-
-
-
-
Chorzow, Poland
-
Lodz, Poland
-
-
-
-
-
San Juan, Puerto Rico
-
-
-
-
-
Nizhny Novgorod, Russian Federation
-
Rostov-Na-Donu, Russian Federation
-
St-Petersburg, Russian Federation
-
St.-Petersburg, Russian Federation
-
-
-
-
-
Barcelona, Spain
-
Salamanca, Spain
-
-
-
-
-
London, United Kingdom
-
Plymouth, United Kingdom
-
-
-
-
California
-
La Jolla, California, United States
-
Los Angeles, California, United States
-
Stanford, California, United States
-
-
Connecticut
-
Norwalk, Connecticut, United States
-
-
Florida
-
Jacksonville, Florida, United States
-
-
Illinois
-
Chicago, Illinois, United States
-
Peoria, Illinois, United States
-
-
Indiana
-
Goshen, Indiana, United States
-
-
Iowa
-
Iowa City, Iowa, United States
-
Sioux City, Iowa, United States
-
-
Kansas
-
Westwood, Kansas, United States
-
-
Kentucky
-
Lexington, Kentucky, United States
-
Louisville, Kentucky, United States
-
-
Louisiana
-
Metairie, Louisiana, United States
-
-
Maryland
-
Baltimore, Maryland, United States
-
-
Massachusetts
-
Boston, Massachusetts, United States
-
Worcester, Massachusetts, United States
-
-
Michigan
-
Ann Arbor, Michigan, United States
-
Detroit, Michigan, United States
-
-
Missouri
-
Jefferson City, Missouri, United States
-
Saint Louis, Missouri, United States
-
-
Nebraska
-
Omaha, Nebraska, United States
-
-
New Jersey
-
Hackensack, New Jersey, United States
-
-
New York
-
New York, New York, United States
-
Syracuse, New York, United States
-
-
South Dakota
-
Watertown, South Dakota, United States
-
-
Tennessee
-
Nashville, Tennessee, United States
-
-
Texas
-
Houston, Texas, United States
-
-
Vermont
-
Burlington, Vermont, United States
-
-
Virginia
-
Charlottesville, Virginia, United States
-
-
West Virginia
-
Morgantown, West Virginia, United States
-
-
Wisconsin
-
Madison, Wisconsin, United States
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Diagnosis of confirmed mantle cell lymphoma (MCL) with at least 1 measurable site of disease according to Revised Response Criteria for Malignant Lymphoma
- Must have received at least 1 prior rituximab-containing chemotherapy regimen, but no more than 5 prior regimens
- Must have received at least 2 cycles of bortezomib therapy (single-agent or in combination) and have documented progressive disease during or after bortezomib therapy
- Eastern Cooperative Oncology Group performance status score 0, 1, or 2
- Hematology and biochemical values within protocol-defined parameters
Exclusion Criteria:
- Prior chemotherapy within 3 weeks, nitrosoureas within 6 weeks, therapeutic anticancer antibodies within 4 weeks, radio- or toxin-immunoconjugates within 10 weeks, radiation therapy or other investigational agents within 3 weeks, or major surgery within 4 weeks of the first dose of study drug
- Prior treatment with ibrutinib or other Bruton's tyrosine kinase inhibitors
- More than 5 prior lines of therapy (separate lines of therapy are defined as single or combination therapies that are either separated by disease progression or by a >6 month treatment-free interval
- Known central nervous system lymphoma
- Diagnosed or treated for malignancy other than MCL, except malignancy treated with curative intent and with no known active disease present for >=3 years before the first dose of study drug and felt to be at low risk for recurrence by the treating physician, adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease, or adequately treated cervical carcinoma in situ without evidence of disease.
- History of stroke or intracranial hemorrhage within 6 months prior to the first dose of study drug
- Requires anticoagulation with warfarin or equivalent vitamin K antagonists
- Requires treatment with strong CYP3A4/5 inhibitors
- Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of Screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by the New York Heart Association Functional Classification
- Known history of human immunodeficiency virus or active infection with hepatitis C virus or hepatitis B virus or any uncontrolled active systemic infection
- Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the patient's safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue risk
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ibrutinib
|
Type=exact number, unit=mg, number=560, form=capsule, route=oral use.
560 mg oral ibrutinib is to be administered once daily continuously until disease progression, unacceptable toxicity, or study end, whichever occurs first.
Doses can be held or reduced based on the severity of and the recovery from side effects of the study drug.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall response rate
Time Frame: 1 year after the last patient is enrolled
|
1 year after the last patient is enrolled
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall survival rate
Time Frame: 1 year after the last patient is enrolled and 2 years after the last patient is enrolled
|
1 year after the last patient is enrolled and 2 years after the last patient is enrolled
|
Progression-free survival rate
Time Frame: 1 year after the last patient is enrolled and 2 years after the last patient is enrolled
|
1 year after the last patient is enrolled and 2 years after the last patient is enrolled
|
Mean change from baseline in the Lym subscale
Time Frame: 1 year after the last patient is enrolled and 2 years after the last patient is enrolled
|
1 year after the last patient is enrolled and 2 years after the last patient is enrolled
|
Mean change from baseline in the EQ-5D-5L index
Time Frame: 1 year after the last patient is enrolled and 2 years after the last patient is enrolled
|
1 year after the last patient is enrolled and 2 years after the last patient is enrolled
|
Mean plasma concentrations of ibrutinib
Time Frame: Up to Cycle 2, Day 21
|
Up to Cycle 2, Day 21
|
Maximum observed plasma concentration of ibrutinib
Time Frame: Up to Cycle 2, Day 21
|
Up to Cycle 2, Day 21
|
Minimum observed plasma concentration of ibrutinib
Time Frame: Up to Cycle 2, Day 21
|
Up to Cycle 2, Day 21
|
Area under the plasma concentration-time curve from time 0 to 24 hours of ibrutinib
Time Frame: Up to Cycle 2, Day 21
|
Up to Cycle 2, Day 21
|
The number of participants affected by an adverse event
Time Frame: Up to 30 days after the last dose of study medication
|
Up to 30 days after the last dose of study medication
|
Overall response rate
Time Frame: 1 year after the last patient is enrolled and 2 years after the last patient is enrolled
|
1 year after the last patient is enrolled and 2 years after the last patient is enrolled
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2012
Primary Completion (Actual)
May 1, 2015
Study Completion (Actual)
May 1, 2015
Study Registration Dates
First Submitted
May 14, 2012
First Submitted That Met QC Criteria
May 15, 2012
First Posted (Estimate)
May 16, 2012
Study Record Updates
Last Update Posted (Estimate)
June 1, 2016
Last Update Submitted That Met QC Criteria
May 27, 2016
Last Verified
May 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CR100847
- PCI-32765MCL2001 (Other Identifier: Janssen Research & Development, LLC)
- 2012-000711-88 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mantle Cell Lymphoma
-
Northwestern UniversityNational Cancer Institute (NCI); Janssen Scientific Affairs, LLCActive, not recruitingStage III Mantle Cell Lymphoma | Stage IV Mantle Cell Lymphoma | Contiguous Stage II Mantle Cell Lymphoma | Noncontiguous Stage II Mantle Cell Lymphoma | Stage I Mantle Cell LymphomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedRecurrent Mantle Cell Lymphoma | Stage III Mantle Cell Lymphoma | Stage IV Mantle Cell Lymphoma | Contiguous Stage II Mantle Cell Lymphoma | Noncontiguous Stage II Mantle Cell Lymphoma | Stage I Mantle Cell LymphomaUnited States
-
National Cancer Institute (NCI)CompletedStage III Mantle Cell Lymphoma | Stage IV Mantle Cell Lymphoma | Contiguous Stage II Mantle Cell Lymphoma | Noncontiguous Stage II Mantle Cell Lymphoma | Stage I Mantle Cell LymphomaUnited States
-
Roswell Park Cancer InstituteNational Comprehensive Cancer NetworkCompletedStage III Mantle Cell Lymphoma | Stage IV Mantle Cell Lymphoma | Stage I Mantle Cell Lymphoma | Stage II Contiguous Mantle Cell Lymphoma | Stage II Non-Contiguous Mantle Cell LymphomaUnited States
-
Burzynski Research InstituteWithdrawnRecurrent Mantle Cell Lymphoma | Stage III Mantle Cell Lymphoma | Stage IV Mantle Cell Lymphoma | Contiguous Stage II Mantle Cell Lymphoma | Noncontiguous Stage II Mantle Cell LymphomaUnited States
-
University of WashingtonNational Cancer Institute (NCI); National Comprehensive Cancer NetworkTerminatedRecurrent Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma | Ann Arbor Stage I Mantle Cell Lymphoma | Ann Arbor Stage II Mantle Cell Lymphoma | Ann Arbor Stage III Mantle Cell Lymphoma | Ann Arbor Stage IV Mantle Cell LymphomaUnited States
-
BeiGeneRecruitingMantle Cell Lymphoma | Relapsed Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma (MCL)United States, China, Israel, Belgium, Poland, Spain, Turkey, Brazil, Italy, Canada, United Kingdom, France, Germany, Argentina, Puerto Rico
-
BeiGeneCompletedRefractory Mantle Cell Lymphoma | Relapsed Mantle Cell LymphomaChina
-
Fondazione Italiana Linfomi - ETSRecruitingRefractory Mantle Cell Lymphoma | Relapsed Mantle Cell LymphomaItaly
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedRecurrent Mantle Cell Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Refractory Mantle Cell Lymphoma | Central Nervous System Lymphoma | Gastric Mantle Cell Lymphoma | Splenic Mantle Cell LymphomaUnited States
Clinical Trials on Ibrutinib
-
Christian BuskeAmgen; Janssen, LPRecruitingWaldenstrom MacroglobulinemiaAustria, Germany, Greece
-
TG Therapeutics, Inc.CompletedMantle Cell Lymphoma | Chronic Lymphocytic LeukemiaUnited States
-
Janssen Research & Development, LLCCompleted
-
Johnson & Johnson Private LimitedCompletedLymphoma, Mantle-Cell | Leukemia, Lymphocytic, Chronic, B-CellIndia
-
Janssen Research & Development, LLCCompleted
-
Oncternal Therapeutics, IncUniversity of California, San Diego; Pharmacyclics LLC.; California Institute...Active, not recruitingMantle Cell Lymphoma | Marginal Zone Lymphoma | B-cell Chronic Lymphocytic Leukemia | Small Lymphocytic LymphomaUnited States
-
The Lymphoma Academic Research OrganisationJanssen Pharmaceutica N.V., BelgiumTerminatedB-cell LymphomaFrance, Belgium
-
Pharmacyclics Switzerland GmbHJanssen Biotech, Inc., including Johnson & JohnsonEnrolling by invitationLymphoma, B-Cell | Lymphoma, Non-Hodgkin | Solid Tumor | Leukemia, B-cell | Graft Vs Host DiseaseUnited States, Spain, Taiwan, United Kingdom, Australia, Italy, Russian Federation, Canada, New Zealand, Korea, Republic of, France, Turkey, Czechia, Hungary, Poland, Sweden
-
Janssen-Cilag Ltd.CompletedLymphoma, Mantle-Cell | Leukemia, Lymphocytic, Chronic, B-CellFrance
-
The Lymphoma Academic Research OrganisationCompletedIntraocular Lymphoma | Primary Central Nervous LymphomaFrance